Furthermore, canakinumab, a human monoclonal antibody targeted against IL-1β that has anti-inflammatory effects, in the “Canakinumab Anti-Inflammatory Thrombosis Outcomes Study” (CANTOS), reduced recurrent cardiovascular events compared to placebo in patients with a history of myocardial infarction and a high degree of hs-CRP, regardless of the lipid lowering effect [84]. The gene discussed is IL1B; the disease is myocardial infarction.